|Summary sheet: DMT|
|Common names||DMT, N,N-DMT, Dmitry, The Glory, The Spirit Molecule|
|Routes of Administration|
N,N-Dimethyltryptamine (also known as DMT, N,N-DMT, Dmitri, and "The Spirit Molecule") is a classical psychedelic substance of the tryptamine class. Among psychedelics, it is known for its unique ability to produce short-lived but intense visionary states and complete hallucinations. It is thought to produce its effects by binding to serotonin receptors in the brain, although the precise mechanism is not fully understood.
DMT is present in over 65 species of plants and has been identified as being a normal constituent of human metabolism and an endogenous neurotransmitter in certain rodents. Its presence is also known to be widespread throughout the plant kingdom. Although various theories have been postulated, its neurobiological function has yet to be determined.
When vaporized or smoked, DMT produces short-lived effects with a very rapid onset that is sometimes described as an "inconceivably high-speed rollercoaster ride." When ingested in combination with a MAOI or RIMA agent, it becomes active orally and significantly longer lasting, immersive, and interactive in nature: this combination is known as ayahuasca. Ayahuasca brews have been used traditionally in South America since at least around the year 1500.
Unlike most highly prohibited substances, DMT has not been proven to be addictive or physiologically toxic. However, adverse reactions such as severe anxiety, delusions and psychosis are always possible, even for experienced users, and particularly for those predisposed to mental disorders.
It is highly advised to use harm reduction practices if using this substance.
History and culture
DMT was first synthesized in 1931 by the German chemist Richard Helmuth Fredrick Manske. Its discovery as a natural product is generally credited to Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima who, in 1946, isolated an alkaloid he named nigerina (nigerine) from the root bark of jurema preta (Mimosa tenuiflora).
It was unequivocally identified in 1959, when American chemists were provided a sample of Mimosa tenuiflora. In 1955, a team of American chemists led by Evan Horning isolated and formally identified DMT in the seeds and pods of Anadenanthera peregrina.
Since 1955, the substance has been found in a host of organisms: in at least fifty plant species belonging to ten families, and in at least four animal species, including one gorgonian and three mammalian species.
DMT, or N,N-dimethyltryptamine, is a member of a family of organic compounds known as tryptamines. Tryptamines share a core structure consisting of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. DMT contains two methyl groups (CH3-) bound to the terminal amine RN at the end of this chain.
It has many homologs and analogs from base tryptamines like MET and DPT, to four and five position substituted variants such as 4-PO-DMT (psilocybin), 4-AcO-DMT (psilacetin), 5-HO-DMT (bufotenin), and 5-MeO-DMT.
Pure DMT is a white, crystalline solid that is often described as smelling like rubber. It is moderately soluble in water, but soluble in organic solvents and aqueous acids.
DMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
In addition to this, N,N-dimethyltryptamine is believed to be an endogenous ligand for the sigma receptor. However, the significance of the sigma-1 receptor remains the subject of ongoing scientific research.
Depending on the dosage and method of administration, the effects of DMT can range from mild psychedelic states to powerfully immersive life-altering experiences which are often described as the ultimate displacement from ordinary consciousness in which users report experiencing ineffable spiritual realms or alternate dimensions. It's also commonly reported to encounter 'beings' of unknown origin after consuming a high dose of DMT. Terrence Mckenna and Dr. Rick Strassman have both studied and popularized this phenomenon. 
DMT in its smokeable form is reported to be the least mentally inebriating psychedelic. It is due to a lack of perceived intoxication that many people describe DMT as a genuine experience that is actually happening to them.
It is worth noting that many people report that smoked DMT is extremely clear-headed in its style and tends to produce less personal insight in comparison to orally active psychedelics such as ayahuasca, LSD and psilocybin due to its short-acting nature.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Spontaneous bodily sensations - The "body high" of DMT can be described as a pleasurable all-encompassing glow. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached. It is capable of becoming very powerful at higher doses and can remain for up to half an hour after the experience itself has ended.
- Changes in felt gravity - At higher breakthrough doses, physical feelings of being launched across vast distances at incredibly high speeds are commonly reported.
- Spatial disorientation
- Changes in felt bodily form
- Physical autonomy
- Nausea - This effect is much less common than it is with 5-MeO-DMT as well as longer-lasting psychedelics like psilocybin mushrooms or mescaline. However, it can still manifest spontaneously and sometimes lead to sudden bouts of vomiting.
- Pupil dilation
- Increased heart rate
- Temperature regulation suppression
- Seizure - This is a very rare effect but is believed to happen in those who are predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
- Drifting (melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in its appearance.
- Colour replacement
- Colour shifting
- Colour tinting
- After images
- Scenery slicing
- Symmetrical texture repetition
- Environmental patterning
The visual geometry encountered can be described as more similar in appearance to that of psilocin than LSD. It can be comprehensively described through its variations as intricate in complexity, abstract in form, equally organic and digital in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in sharp and soft edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in its intensity. At higher doses, it is significantly more likely to result in states of level 8B visual geometry over level 8A.
The geometry present with smokeable DMT is considered by many to be the most profoundly intricate and complex set of visual geometry found within the entirety of the psychedelic experience. In comparison to orally active DMT (ayahuasca), it is significantly more digital in appearance and contains a colour scheme which is similar to LSD and a structured style that resembles a high dose of psilocin (4-HO-DMT).
DMT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic. These effects include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - DMT produces high level internal hallucinations at appropriate doses more consistently than that of any other psychedelic. They are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- Analysis enhancement
- Déjà vu
- Ego replacement
- Emotion enhancement
- Euthymia - This effect manifests itself acutely for all classical psychedelics when one to three doses are combined with a psychotherapy treatment program. When comparing meta analyses, psychedelic psychotherapy greatly outperforms "gold standard" treatments for several mental health problems.
- Cognitive euphoria
- Feelings of impending doom
- Increased music appreciation - This typically occurs only at lower sub-breakthrough doses, and is not as prominent of an effect as it is with longer lasting psychedelics like LSD or psilocybin. Many people prefer to have their DMT experiences in complete silence, other than shutting out perceptual distractions this is often done to prevent a muddled or overwhelming experience.
- Memory suppression
- Mindfulness - This effect tends to occur after the experience has ended and the individual has returned to ordinary waking consciousness, to a sense of presence and sensitivity towards one's inner sensations as well as outer environment.
- Multiple thought streams - This effect tends to manifest in a much more chaotic fashion, in tandem with the sensation of cognitive overload.
- Novelty enhancement
- Personal bias suppression
- Rejuvenation - This effect tends to occur after the experience has ended and the subject has returned to ordinary waking consciousness, often in Near-Death Experience (NDE) variants of a DMT experience.
- Autonomous voice communication
- Time distortion - This effect is a very prominent aspect of the DMT experience, which only tends to last under 15 minutes but is commonly reported to subjectively feel as if it had lasted much longer, in some cases "many lifetimes" or even an "eternity". This particular effect is most prevalent and notable with "breakthrough" experiences.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
- For a number of individuals these effects are consistently more reproducible and powerful with smoked or vaporized DMT than they are with other “classical psychedelics” such as LSD or mescaline, this is most likely due to its very intense but relatively short-lived effects. These components are unique to DMT in that for a majority of its users they are significantly more likely to manifest during "breakthrough" experiences as opposed to sub-breakthrough level experiences.
When smoked or vaporized at moderate to heavy dosages, the DMT experience consistently manifests itself in a progressive sequence which can be described as follows:
1. "Breaking Through"
The first step of a DMT trip is the come up that leads onto an experience commonly referred to as "breaking through." This seems to have at least a few different ways of presenting itself to the user.
The first thing that a person notices is an extremely distinct set of visual enhancements such an increase in visual acuity and colour intensity. This is followed by a sudden onset of high level 3 geometry which increases in its intensity until it envelopes and covers the external environment. These effects are often accompanied by auditory hallucinations such as soft crackling sounds or high pitched extended tones. There is also the possibility of accompanying physical sensations as one "breaks through." These can include feelings of suddenly being pushed through and onto the other side of a membrane or feelings of shooting through space at high speeds.
2. "The Waiting Room"
Almost immediately after a person has inhaled enough DMT to have "broken through", they often find themselves spending a brief amount of time in what is sometimes described as a psychedelic "waiting room" or "loading screen." The appearance of this space can assume a seemingly infinite variety of forms but generally appears in the shape of an enveloping tunnel comprised of rapidly shifting, interlocking geometry. This lasts approximately 10 – 20 seconds and feels qualitatively different from other stages of the experience.
3. "The Other Side"
Once the waiting period is over, the user will feel that they have "broken through" onto the other side. It is here where users experience intense level 7 geometry and level 3 - 4 internal hallucinations. It is worth noting that although experiences vary between individuals, DMT trips often follow common archetypes, scenarios, content, and plots. These scenarios generally consist of visiting what appears to be an alternate reality that is often described to contain autonomous entities, settings, sceneries, and landscapes as well as themes of a cosmic, transcendental, or transpersonal nature.
4. "Drifting Down"
The final stage is experienced as the sensation of being pulled further and further away from the scenario until it is no longer visible and one finds themselves back in reality. This is typically accompanied by level 3 - 4 geometry as well as a sense of general exhilaration and awe. The moderate to mild geometry stays for a further 10 – 15 minutes before disappearing completely, sometimes leaving a noticeable "body high" that lingers for up to an hour.
Anecdotal reports which describe the effects of this compound within our experience index include:
- Experience: 100ug ALD-52 - Nice weekend trip
- Experience: 25mg 50% DMT Changa + Cannabis (Smoked - Bong) - Insights into my consciousness
- Experience:2.5g Mushrooms + 500mg DMT
- Experience:25mg DMT - Your wall can't save you
- Experience:300mg DXM + 25mg DMT + Cannabis - A crazy night
- Experience:30mg (smoked) DMT - The Monolith
- Experience:337mg DMT fumarate - A Day With DMT
- Experience:40mg (smoked) - The planet became a watermelon
- Experience:40mg DMT - Second breakthrough
- Experience:40mg smoked - Ego death and unity with a friend
- Experience:50mg - Demon faces and déjà vu
- Experience:50mg - Truth
- Experience:75mg DMT - Experiencing Death
- Experience:80mg - progressing deeper into states of unity and interconnectedness
- Experience:An Excessive Amount - N,N DMT / Marijuana - Stuck Inside an Egg
- Experience:DMT (30mg, glass pipe) - First DMT trip ever turned therapeutic
- Experience:DMT (60mg, freebase) - passing out
- Experience:DMT (75 mg, smoked) - Bad trip with illustration
- Experience:DMT (unknown dose, smoked) - It felt like I was on rails the whole time
- Experience:DMT (unknown, smoked/vaporized) - She Struggles then Finds Beauty and the Nature of DMT Itself
- Experience:DMT (unknown, smoked/vaporized) - Unexpected Correspondences
- Experience:DMT (~50mg) + Cannabis - Geometric Angels
- Experience:DMT: 1,1mg 1/5 changa x3 – The continuation
- Experience:DMT: 200mg 1/5 changa - Bad yet glorious trip
- Experience:DXM (340 mg) + DMT (30 mg, smoked) + Cannabis - Amazing Synergy
- Experience:MDMA (750mg, Oral) - Finally Free
Additional experience reports can be found here:
Natural plant sources
Mimosa hostilis root bark
Mimosa hostilis (also known as Mimosa tenuiflora, Jurema and Tepezcohuite) is a perennial tree or shrub native to the northeastern region of Brazil and is found as far north as southern Mexico. Around 1% of the dried weight is DMT. It is legal to purchase online in many parts of the world and a commonly used source for performing DMT extractions or brewing into ayahuasca.
Acacia confusa root bark
Acacia confusa (also known as Acacia Petit Feuille, Small Philippine Acacia, Formosa Acacia (Taiwan Acacia) and Formosan Koa) is a perennial tree native to South-East Asia. It is legal to purchase online and easily accessible in many parts of the world. The plant matter itself contains the following chemicals:
- N-Methyltryptamine: 1.43% (not psychoactive without MAOI)
- DMT: 1.15%
Preparation methods for this substance found within our tutorial index include:
- DMT extraction using sodium hydroxide and naphtha
- Acid-base DMT extraction, based on Marsofold's tek
- D-Limonene and vinegar DMT extraction
- Norman Tek
- DMT ingestion methods
Dr. Rick Strassman has hypothesized that the pineal gland is responsible for the production and release of DMT which he believes possibly could be excreted in large quantities at the moments of birth and death. However, this view was contested by David E. Nichols in 2018, who argued that the pineal gland secretes insufficient amounts of DMT to produce psychoactive effects.
In 2019, a study by Jimo Borjigin demonstrated in rat brains that brain neurons with the two enzymes required to make DMT were not just in the pineal gland but also in the neocortex and hippocampus.
A 2018 study found significant relationships between a DMT experience and a near-death experience. A 2019 large-scale study found that ketamine, Salvia divinorum, and DMT (and other classical psychedelic substances) are linked to near-death experiences.
In September 2020, an in vitro and in vivo study showed that DMT present in the ayahuasca infusion promotes neurogenesis.
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test.
|Yellow - Orange - Brown||Yellow - Green - Dark green||(faint) Green - Brown||Black||No reaction||No reaction||Pink - magenta||Yellow||No reaction|
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
DMT is considered to be non-addictive, is not associated with any form of neurotoxicity, and has an extremely low toxicity relative to dose. As with other psychedelic substances, there are relatively few physical side effects associated with acute DMT exposure. Various studies have shown that in reasonable doses in a careful context, it has little to no negative cognitive, psychiatric or physical consequences.
However, as with psychedelics generally, DMT is thought to be able to act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are advised not to use this substance unless under medical supervision.
Despite the lack of physical risks, it is highly advised to approach this substance with extreme caution and harm reduction practices.
The median lethal dose (LD50) of DMT in humans has never been reached in any setting, nor is this expected to change due to its pharmacological properties.
Dependence and abuse potential
Like other serotonergic psychedelics, DMT is considered to be non-addictive with a low abuse potential. There are no literature reports of successful attempts to train animals to self-administer DMT — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence. Likewise, there is virtually no withdrawal syndrome when chronic use of DMT is stopped.
Notably, tolerance to the effects of DMT does not appear to occur. The reason for this is unknown. Likewise, DMT does not produce cross-tolerance with other psychedelics, meaning that after the consumption of DMT, psychedelics will not have a reduced effect.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of DMT. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
Internationally, DMT is classified as a Schedule I controlled substance under the United Nations 1971 Convention on Psychotropic Substances, meaning that international trade in DMT is supposed to be closely monitored and its use is supposed to be restricted to scientific research and medical use. Natural materials containing DMT, including ayahuasca, are not regulated under the 1971 Psychotropic Convention.
- Australia: DMT is controlled under Schedule 9 of the Poisions Standard. A schedule 9 drug is outlined in the Poisons Act 1964 as "Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO." Under the Misuse of Drugs act 1981 6.0 g of DMT is considered enough to determine a court of trial and 2.0 g is considered intent to sell and supply. Between 2011 and 2012, the Australian Federal Government was considering changes to the Australian Criminal Code that would classify any plants containing any amount of DMT as "controlled plants". DMT itself was already controlled under current laws. The proposed changes included other similar blanket bans for other substances, such as a ban on any and all plants containing Mescaline or Ephedrine. The proposal was not pursued after political embarrassment on realisation that this would make the official Floral Emblem of Australia, Acacia pycnantha (Golden Wattle), illegal. The Therapeutic Goods Administration and federal authority had considered a motion to ban the same, but this was withdrawn in May 2012 (as DMT may still hold potential entheogenic value to native and/or religious people).
- Austria: DMT is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
- Belgium: DMT is illegal to possess, sell, purchase and import.
- Brazil: DMT is illegal to possess, produce and sell under Portaria SVS/MS nº 344. Rules are relaxed regarding religious use.
- Canada: DMT is listed in Schedule III of the Controlled Drugs and Substances Act.
- Denmark: DMT is a Category B controlled substance.
- Estonia: DMT is a Schedule I controlled substance.
- France: DMT is classified as a narcotic.
- Hungary: DMT is illegal to possess, produce and sell.
- Germany: DMT is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 24, 1974. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Ireland: DMT is a Schedule 1 controlled substance under the Misuse of Drugs Acts.
- Israel: DMT is an illegal substance. Production, trade and possession are prosecuted as crimes.
- India: DMT is illegal to produce, transport, trade in or possess.
- Italy: DMT is a Schedule I controlled substance.
- Latvia: DMT is a Schedule I controlled substance.
- The Netherlands: DMT is classified as a Lijst 1 (List I) controlled substance under the Opiumwet (Opium Law).
- New Zealand: DMT is classified in New Zealand as a Class A controlled substance under the Misuse of Drugs Act 1975.
- Norway: DMT is a Schedule I controlled substance.
- Russia: DMT is a список I (List I) contolled substance. It is illegal to possess, produce and sell.
- Serbia: DMT is a List 4 controlled substance.
- Sweden: DMT is controlled under Förteckning I (Schedule 1). The Swedish supreme court concluded in 2018 that possession of processed plant material containing a significant amount of DMT is illegal. However, possession of unprocessed such plant material was ruled legal.
- Switzerland: DMT is a controlled substance specifically named under Verzeichnis D.
- United Kingdom: DMT is a Class A controlled substance.
- United States: DMT is a Schedule I controlled substance. Rules are relaxed regarding religious use, however. In the US, dried root bark of Mimosa hostilis had been considered a "grey area" item for a long time. However, recent efforts by the DEA appear to be focusing on eliminating internet sales of the bark, citing 21 USC § 841, which states that "(IV) any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subclauses (I) through (III)" is also considered an illegal substance. Many USA based vendors have since been stocking Acacia confusa bark as a result due to its very similar alkaloid content.
- Czech Republic: DMT is a Schedule I controlled substance.
- Nichols, D. E. (2016). Psychedelics, (April), 264–355. https://doi.org/10.1124/pr.115.011478
- Strassman, R. J. (1995). Human psychopharmacology of N, N-dimethyltryptamine. Behavioural Brain Research, 73(1), 121-124. https://doi.org/10.1016/0166-4328(96)00081-2
- Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale. Archives of General Psychiatry, 51(2), 98-108. PMID: 8297217.
- Nichols, David E. (2016). Barker, Eric L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478. eISSN 1521-0081. ISSN 0031-6997.
- Ott, Jonathan (1994). Ayahuasca Analogues: Pangæan Entheogens (1st ed.). Kennewick, WA, USA: Natural Products. pp. 81–83. ISBN 978-0-9614234-5-2. OCLC 32895480.
- Shulgin, Alexander; Shulgin, Ann (1997). "DMT is Everywhere". TiHKAL: The Continuation. United States: Transform Press. p. 277. ISBN 0-9630096-9-9. OCLC 38503252.
- Strassman, Rick J. (1995). "Human psychopharmacology of N,N-dimethyltryptamine". Behavioural Brain Research. 73 (1-2): 121–124. doi:10.1016/0166-4328(96)00081-2. eISSN 1872-7549. ISSN 0166-4328. OCLC 06183451.
- "Erowid DMT Vault: Basics". Erowid. August 22, 2000. Retrieved January 7, 2020.
- Lüscher, Christian; Ungless, Mark A. (2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11). doi:10.1371/journal.pmed.0030437. ISSN 1549-1277. PMID 17105338.
- Strassmann, Rick (1984). "Adverse reactions to psychedelic drugs. A review of the literature". Journal of Nervous and Mental Disease. 172 (10): 577–595. doi:10.1097/00005053-198410000-00001. ISSN 0022-3018. OCLC 1754691. PMID 6384428.
- "q21q21" (September 19, 2014). "Q21Q21 tek (and other limeteks) NOT recommended for shredded bark!". DMT Nexus. Retrieved January 8, 2020.
- Manske R. H. F. (1931). "A synthesis of the methyltryptamines and some derivatives". Canadian Journal of Research. 5 (5): 592–600. doi:10.1139/cjr31-097. ISSN 0366-6581.
- Bigwood J.; Ott J. (1977). "DMT: the fifteen minute trip". Head. 2 (4): 56–61. Archived from the original on January 27, 2006. Retrieved November 28, 2010.
- Strassman, R. J.; Qualls, C. R.; Uhlenhuth, E. H.; Kellner, R. (1994). "Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale" (PDF). Archives of General Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. eISSN 1538-3636. ISSN 2168-622X. PMID 8297217.
- Ott, Jonathan (1996). Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History (2nd, densified ed.). Kennewick, WA: Natural Products. ISBN 978-0-9614234-9-0.
- Pachter I. J.; Zacharias D. E.; Ribeiro O. (1959). "Indole alkaloids of Acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis". The Journal of Organic Chemistry. 24 (9): 1285–87. doi:10.1021/jo01091a032. eISSN 1520-6904. ISSN 0022-3263.
- Fish M. S.; Johnson N. M.; Horning E. C. (1955). "Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species". Journal of the American Chemical Society. 72 (22): 5892–95. doi:10.1021/ja01627a034. eISSN 1520-5126. ISSN 0002-7863.
- Cimino G.; De Stefano S. (1978). "Chemistry of Mediterranean gorgonians: simple indole derivatives from Paramuricea chamaeleon". Comparative Biochemistry and Physiology C. 61 (2): 361–2. doi:10.1016/0306-4492(78)90070-9.
- Erowid DMT Vault : Profiles of Psychedelic Drugs - DMT
- Fontanilla, D.; Johannessen, M.; Hajipour, A. R.; Cozzi, N. V.; Jackson, M. B.; Ruoho, A. E. (2009). "The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator". Science. 323 (5916): 934–937. doi:10.1126/science.1166127. eISSN 1095-9203. ISSN 0036-8075. OCLC 1644869. PMC . PMID 19213917.
- Gallimore, Andrew R.; Strassman, Rick J. (2016). "A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience". Frontiers in Pharmacology. 7 (211). doi:10.3389/fphar.2016.00211. eISSN 1663-9812. PMC . PMID 27471468.
- Morales-Garcia, JA; Calleja-Conde, J; Lopez-Moreno, JA; Alonso-Gil, S; Sanz-SanCristobal, M; Riba, J; Perez-Castillo, A (28 September 2020). "N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo". Translational psychiatry. 10 (1): 331. doi:10.1038/s41398-020-01011-0. PMID 32989216.
- Timmermann, C., Roseman, L., Williams, L., Erritzoe, D., Martial, C., Cassol, H., Laureys, S., Nutt, D., Carhart-Harris, R. (15 August 2018). "DMT Models the Near-Death Experience". Frontiers in Psychology. 9: 1424. doi:10.3389/fpsyg.2018.01424. ISSN 1664-1078.
- Martial, C; Cassol, H; Charland-Verville, V; Pallavicini, C; Sanz, C; Zamberlan, F; Vivot, RM; Erowid, F; Erowid, E; Laureys, S; Greyson, B; Tagliazucchi, E (March 2019). "Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports". Consciousness and cognition. 69: 52–69. doi:10.1016/j.concog.2019.01.011. PMID 30711788.
- Strassman, Rick J. (2001). DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Rochester, Vt: Park Street. ISBN 978-0-89281-927-0. OCLC 45195642. ("Chapter summaries". Retrieved 27 February 2012.)
- Nichols, David E. (2018). "N,N-dimethyltryptamine and the pineal gland: Separating fact from myth". Journal of Psychopharmacology. doi:10.1177/0269881117736919. eISSN 1461-7285. ISSN 0269-8811. OCLC 19962867. PMID 29095071.
- "'Mystical' psychedelic compound found in normal brains". Neuroscience News. June 27, 2019. Retrieved January 8, 2020.
- Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. doi:10.1016/j.celrep.2018.05.022. ISSN 2211-1247. PMID 29898390. PMC 6082376.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- "Convention On Psychotropic Substances, 1971" (PDF). United Nations Office on Drugs and Crime. Retrieved January 3, 2020.
- Herbert Schaepe (International Narcotics Control Board) (January 17, 2001). "International control of the preparation "ayahuasca"". Erowid. Retrieved January 8, 2020.
- "Poisons Standard December 2019". Federal Register of Legislation. Office of Parliamentary Counsel. November 14, 2019. Retrieved January 8, 2020.
- "Poisons Act 1964" (PDF). State Law Publisher. July 2, 2014. Archived from the original (PDF) on December 22, 2015.
- "Misuse of Drugs Act 1981" (PDF). State Law Publisher. Archived from the original (PDF) on December 22, 2015.
- "Consultation on implementation of model drug schedules for Commonwealth serious drug offenses". Australian Government, Attorney-General's Department. June 24, 2010. Archived from the original on 7 November 2011.
- "Aussie DMT Ban". American Herb Association Quarterly Newsletter. Vol. 27 (3). August 2012. p. 14.
- "Wetgeving rond LSD en tripmiddelen" (in Dutch). Druglijn. Retrieved October 23, 2020.
- "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária [National Sanitary Surveillance Agency]. December 5, 2016. p. 22. Retrieved January 8, 2020.
- "Schedule III". Controlled Drugs and Substances Act (S.C. 1996, c. 19). Government of Canada. Retrieved January 1, 2020.
- "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Danish Medicines Ageny. August 31, 2015. Retrieved January 1, 2020.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in German). Bundesanzeiger Verlag. January 23, 1974. pp. 97–98. Retrieved January 7, 2020.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Schedule: Controlled Drugs". Misuse of Drugs Act, 1977. Government of Ireland. Retrieved October 23, 2020.
- Senyor, Eli (August 6, 2013). "Judge's son arrested for importing 2kg of hallucinogenic drug". Ynetnews. Tel Aviv: Yediot Ahronot. Retrieved August 11, 2017.
- Dr. G. Shreekumar Menon. "The God Drug - DMT". Mangalore Today. Retrieved October 23, 2020.
- "Tabella I" (PDF) (in Italian). Ministero della Salute [Ministry of Health]. p. 8. Archived from the original (PDF) on July 13, 2019. Retrieved January 7, 2020.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- "Opiumwet" (in Dutch). Ministerie van Binnenlandse Zaken en Koninkrijksrelaties [Ministry of the Interior and Kingdom Relations]. January 1, 2020. Retrieved January 8, 2020.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "Постановление Правительства РФ от 30.06.1998 N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)" (in Russian). ГАРАНТ [GARANT]. Retrieved January 8, 2020.
- "Läkemedelsverkets författningssamling" (PDF) (in Swedish). Christina Rångemark Åkerman (Läkemedelsverket [Swedish Medical Products Agency]). September 21, 2011. p. 12. ISSN 1101-5225. Archived from the original (PDF) on July 22, 2019.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
- Controlled Substances (PDF), US DOJ, 2022
- email@example.com, A. C.-, 463/2013 Sb. Nařízení vlády o seznamech návykových látek